Literature DB >> 10048900

Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss.

A Strawford1, T Barbieri, R Neese, M Van Loan, M Christiansen, R Hoh, G Sathyan, R Skowronski, J King, M Hellerstein.   

Abstract

Serum testosterone concentrations are frequently in the low-normal range (lowest quartile, <500 ng/dl) in men with AIDS-wasting syndrome (AWS) and in other chronic wasting disorders. The response of patients in this group to androgen treatment has not been determined, however. Eighteen men with AWS (mean +/- standard error [SE]: 87% +/- 1% usual body weight; CD4 count 90 +/- 24) and borderline low serum testosterone concentrations (382 +/- 33 ng/dl) completed a 21-day placebo-controlled inpatient metabolic ward study comparing intramuscular (i.m.) placebo (n = 7) with low-dose (65 mg/week; n = 4) and high-dose (200 mg/week; n = 7) nandrolone decanoate, a testosterone analogue. Nitrogen balance, stable isotope-mass spectrometric measurement of de novo lipogenesis (DNL), resting energy expenditure, and gonadal hormone levels were measured. Both low-dose and high-dose nandrolone resulted in significant nitrogen retention (33-52 g nitrogen/14 days, representing gains of 0.5 to 0.9 kg lean tissue/week) compared with placebo (loss of 11 g nitrogen/week). This was reflected biochemically in a borderline significant reduction of high DNL (p < .06). Serum testosterone and gonadotropins were suppressed whereas resting energy expenditure was unchanged by nandrolone treatment. In 10 study subjects completing a 12-week open-label follow-up phase, body weight increased by 4.9 +/- 1.2 kg, including 3.1 +/- 0.5 kg lean body mass, and treadmill exercise performance also improved. In summary, nandrolone decanoate therapy in the absence of an exercise program in borderline hypogonadal men with AWS caused substantial nitrogen retention compared with placebo, similar in extent to the nitrogen retention previously achieved with recombinant growth hormone. It is reasonable to expand the criteria for androgen treatment in AWS to include at least patients in the lowest quartile of serum testosterone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048900     DOI: 10.1097/00042560-199902010-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  5 in total

1.  Metabolic Complications of HIV and AIDS.

Authors:  Alison Strawford; Marc K. Hellerstein
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

Review 2.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

3.  Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels.

Authors:  S Bhasin; T W Storer; M Javanbakht; N Berman; K E Yarasheski; J Phillips; M Dike; I Sinha-Hikim; R Shen; R D Hays; G Beall
Journal:  JAMA       Date:  2000-02-09       Impact factor: 56.272

Review 4.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

5.  Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones.

Authors:  Krystian Josiak; Ewa A Jankowska; Massimo F Piepoli; Waldemar Banasiak; Piotr Ponikowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-08-01       Impact factor: 12.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.